



May 11, 2023

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

**Sub: Press Release on Audited Financial Results (Standalone and Consolidated)
for the Quarter and Financial Year ended March 31, 2023**

Dear Sir/ Madam,

Please find enclosed herewith the Press Release on the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023.

We request you to please take the same on record.

Thanking You,
Yours Faithfully,

For Dr. Lal PathLabs Limited

Ved Prakash Goel
Group Chief Financial Officer

Encl.: As above

Dr Lal PathLabs Limited records revenue of Rs 491 Cr in Q4 FY 2022-23

New Delhi, India, May 11, 2023 – Dr Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2023.

Consolidated Performance Highlights: Q4 FY 2022-23 vs Q4 FY 2021-22

- Non-Covid Revenue increased by 14.4% in Q4 FY23 & 15.5% in FY23
- Normalised EBITDA margin (after adjustment for stock based compensation, CSR & exceptional expenses) for Q4 FY23 is 26.6% & 26.2% for FY23
- Normalised PAT* margin for Q4 FY23 is 15.5% and 14.7% for FY23

Financial Overview (Consolidated) in Rs Cr

Particulars	Q4			FY		
	FY23	FY22	Gr %	FY23	FY22	Gr %
Revenue	491	486	1.1%	2017	2087	-3.4%
<i>Non Covid</i>	480	420	14.4%	1954	1691	15.5%
<i>Covid & Allied</i>	11	66	-83.4%	63	396	-84.1%
Operating Expenditure	360	355	1.5%	1489	1487	0.1%
Normalised EBITDA	131	131	0.0%	528	600	-12.1%
<i>Margins</i>	26.6%	26.9%		26.2%	28.8%	
RSU & CSR cost	8	10		31	40	
Exceptional Item	7	0		7	0	
EBITDA	116	121	-4.4%	490	561	-12.6%
<i>Margins</i>	23.6%	24.9%		24.3%	26.9%	
Other Income	14	12		42	53	
Depreciation Cost	38	38		150	108	
EBIT	92	95	-3.2%	381	505	-24.5%
Finance Cost	9	12		38	30	
PBT	83	84	-0.3%	344	475	-27.6%
<i>Margins</i>	17.0%	17.2%		17.0%	22.8%	
PAT	57	62	-8.2%	241	350	-31.2%
<i>Margins</i>	11.6%	12.8%		12.0%	16.8%	
EPS	6.8	7.4	-7.8%	28.8	41.7	-30.9%
Normalised PBT*	102	94	8.2%	400	494	-19.0%
<i>Margins</i>	20.8%	19.4%		19.8%	23.7%	
Normalised PAT*	76	73	4.1%	297	369	-19.5%
<i>Margins</i>	15.5%	15.0%		14.7%	17.7%	
Normalised EPS*	9.1	8.7	4.5%	35.5	44.0	-19.2%

*Normalised PBT and PAT are excluding notional depreciation of Rs. 12 Cr. in Q4 FY23, Rs. 49 Cr. in FY23 and Rs. 11 Cr. in Q4 FY22, Rs. 19 Cr. in FY22 and exceptional expenses of Rs. 7 Cr.in Q4 and FY'23.



About Dr Lal PathLabs Limited

Dr Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2023 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata, Bangalore & Mumbai), 5,102 Patient Service Centers (PSCs) and 10,938 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Goel
Group Chief Financial Officer
Dr Lal PathLabs Limited

+91 124 3016500
cfo@lalpathlabs.com

Rakshit Tewari/ Kritika Khatwani
Adfactors PR

+91 9935551036/+91 8604801332
rakshit.tewari@adfactorspr.com
kritika.khatwani@adfactorspr.com

For further information on Dr Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.